Post-SSRI Sexual Dysfunction

PSSD — The antidepressant that took away feeling

SSRIs are prescribed to over 60 million Americans every year. For some, the sexual and emotional side effects never go away — even after stopping the drug.

What is PSSD?

Post-SSRI Sexual Dysfunction (PSSD) is a condition in which sexual, neurological, and emotional side effects persist indefinitely after discontinuing SSRI or SNRI antidepressants. Patients report genital numbness, loss of libido, emotional blunting, and anhedonia that do not resolve weeks, months, or even years after stopping the medication.

SSRIs work by blocking the reuptake of serotonin, flooding synapses with excess serotonin. Research suggests that prolonged serotonin receptor down-regulation and epigenetic changes to gene expression may underpin the persistence of symptoms. The exact mechanism remains unclear, and to date no pharmaceutical company has publicly funded research into the condition.

The European Medicines Agency (EMA) formally recognized PSSD in 2019, requiring updated product labels for SSRIs and SNRIs across Europe. Despite this milestone, most prescribing physicians remain unaware of the condition, and no diagnostic test or approved treatment exists.

Symptoms

Persistent symptoms reported by patients

PSSD affects sexual function, neurological health, and physical wellbeing. Symptoms may appear during SSRI use and persist after stopping, or emerge upon discontinuation.

Sexual

Genital numbness / reduced sensation
Complete loss of libido
Erectile dysfunction
Pleasureless or muted orgasms
Vaginal dryness

Neurological

Emotional blunting
Anhedonia (inability to feel pleasure)
Depersonalization / derealization
Cognitive fog and memory issues
Insomnia and sleep disruption

Physical

Chronic fatigue
Reduced tactile sensation
Muscle weakness

The Numbers

PSSD by the numbers

3,210

EudraVigilance reports

46,000+

Estimated US cases (0.46% prevalence)

60M+

Annual US SSRI prescriptions

32 years

Before formal regulatory recognition

14.7x

Higher rate of reduced genital sensitivity in SSRI users vs other medications

Source: PSSD cross-sectional survey, 2024

Regulatory Timeline

A history of delayed recognition

1987

Prozac approved by FDA

Clinical trials report sexual dysfunction in 2-16% of participants. Manufacturer later accused of under-reporting.

2012

GSK $3 billion settlement

GlaxoSmithKline pays the largest healthcare fraud settlement in US history, partly related to Study 329 and the promotion of Paxil (paroxetine) to children.

2019

EMA recognizes PSSD

The European Medicines Agency formally acknowledges that SSRI/SNRI sexual dysfunction can persist after discontinuation. Product labels updated across Europe.

2022

MedDRA code adopted

PSSD receives its own MedDRA adverse-event code, enabling standardized global pharmacovigilance reporting for the first time.

2025

Public Citizen petition dismissed

A petition to the FDA by Public Citizen requesting stronger warnings is dismissed, leaving US patients without adequate regulatory protection.

Key Research

Published science on PSSD

All PSSD research to date has been patient-funded or conducted by independent academics. No pharmaceutical company has publicly contributed to PSSD research.

Healy et al.

Characterization of PSSD as a distinct clinical entity with persistent sexual dysfunction, emotional blunting, and cognitive impairment following SSRI use.

Giatti et al. (2025)

Demonstrated that paroxetine causes persistent changes to dopamine pathways in animal models, providing a potential neurobiological mechanism for PSSD.

Csoka & Szyf (2009)

Proposed that SSRIs induce epigenetic changes (DNA methylation and histone modifications) that persist after drug withdrawal, underpinning the chronicity of PSSD.

Rice et al. (2025)

Qualitative study documenting patient experiences with PSSD, highlighting the psychosocial impact and the difficulty many patients describe in having their symptoms recognised.

The Drugs

The drugs involved

PSSD has been reported with all major SSRIs and SNRIs. Risk varies by drug, with paroxetine consistently showing the highest incidence of persistent sexual side effects.

Highest reported risk

Paroxetine

Paxil / Seroxat

Subject of the largest healthcare fraud settlement in US history ($3B, GSK, 2012). Study 329 showed it was ineffective in adolescents while GSK promoted it for children. Most frequently cited in PSSD case reports.

Sertraline

Zoloft

One of the most widely prescribed SSRIs globally. Frequently reported in PSSD cases, particularly for persistent genital numbness and emotional blunting.

Fluoxetine

Prozac

The first SSRI approved by the FDA (1987). Clinical trials reported sexual dysfunction in 2-16% of participants. The manufacturer was subsequently accused of under-reporting true incidence.

Escitalopram

Lexapro / Cipralex

A newer SSRI often marketed as having fewer side effects. PSSD cases continue to be reported, particularly involving loss of libido and anorgasmia.

Citalopram

Celexa

The racemic parent compound of escitalopram. Associated with persistent sexual dysfunction and emotional numbing in post-marketing reports.

Venlafaxine

Effexor

An SNRI (serotonin-norepinephrine reuptake inhibitor). Known for severe withdrawal effects and persistent sexual dysfunction after discontinuation.

Duloxetine

Cymbalta

Another SNRI prescribed for depression, anxiety, and pain. Reports of persistent sexual and emotional side effects after stopping continue to accumulate.

The Reporting Gap

The gap between reality and the data

PSSD is one of the most underreported adverse drug reactions in modern medicine. The numbers reveal a system that systematically obscures the true scale of harm.

134 reported

46,000+ estimated

0.3% Capture rate

No ICD code

PSSD still has no International Classification of Diseases (ICD) code, meaning doctors cannot formally diagnose it. Without a code, the condition is invisible to health systems, insurance databases, and epidemiological research. Patients are coded under generic categories like "sexual dysfunction NOS," erasing PSSD from the medical record entirely.

Patients don't connect the dots

Many patients are never told that SSRIs can cause persistent sexual dysfunction. When symptoms continue after stopping the drug, they blame ageing, stress, or their underlying depression — not the medication. Doctors frequently reinforce this misattribution.

Doctors dismiss reports

Patients who do recognise the connection often face clinical dismissal. Studies show that physicians frequently attribute PSSD symptoms to the original psychiatric condition rather than the drug itself, discouraging formal adverse event reporting.

Pharma benefits from silence

Low reporting rates allow pharmaceutical companies to characterise the condition as rare. SSRIs generate billions in annual revenue globally. To date, no manufacturer has publicly funded a study into PSSD.

Take Action